Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive’s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
Lyell Immunopharma announced in an October 24, 2022, SEC filing that GlaxoSmithKline (GSK) had informed the company of the decision to terminate an agreement regarding its development of several investigational cell therapy products which target NY-ESO-1 and utilize Lyell’s genetic and epigenetic reprogramming technologies.
Rznomics’s RZ-001, an investigational ribozyme-based RNA reprogramming therapy, has received clearance of its investigational new drug (IND) application from the FDA, which will allow for initiation of a phase 1/2a clinical trial for patients with hepatocellular carcinoma (HCC).
AVROBIO’s AVR-RD-02, an investigational gene therapy intended to treat Gaucher disease type 1, has received rare pediatric disease designation from the FDA. It also received ILAP designation in the UK earlier in October.
Myeloid Therapeutics’ MT-101, an investigational autologous mRNA engineered chimeric antigen receptor (CAR) monocyte therapy, has received fast track designation from the FDA for the treatment of patients with relapsed or refractory (r/r) CD5+ peripheral T-cell lymphoma (PTCL).
As part of the memorandum of understanding signed between the 2 companies, Polyplus will provide support to the optimization projects taking place at 2 of ENCell's South Korean facilities.
The strategic partnership between the 2 CDMOs will enable them to offer customers manufacturing services for both plasmid DNA and viral vectors in a streamlined process.
Eudora will utilize Replay's synHSV technology and pursue gene therapies for indications including retinitis pigmentosa, Stargardt disease, and Usher syndrome type 1B.
Axicabtagene Ciloleucel Injection (YIKAIDA) is listed for priority review for the treatment of patients with large B-cell lymphoma who did not respond to first-line immunochemo therapy or relapsed in 12 months or less post-treatment.
Michael Andreeff, MD, PhD, professor of leukemia, The University of Texas MD Anderson Cancer Center, will investigate the ability of Eterna's investigational induced pluripotent stem (iPS) cell therapies, which are intended to treat various indications such as acute myeloid leukemia and solid tumors, to initiate enhanced immune responses and promote multilineage differentiation and hematopoietic regeneration.
The collaboration is focused on research and development for cell therapies that use Obsidian’s cytoDRiVE technology for controlled expression of CD40L.
Atossa expects that the investment in Dynamic Cell Therapies, which is in the process of developing CAR-T therapies for difficult-to-treat cancers, will put the company in a strategic position for future CAR-T therapy-related opportunities.